NEW YORK (GenomeWeb News) – Fitch Ratings today affirmed Bio-Rad's ratings, noting the firm's stability and strong cash position but warning against continued macroeconomic headwinds.

Included in the ratings is a BBB- for Issuer Default Rating; BBB- for senior secured bank facility; BBB- for senior unsecured notes; and BB+ for senior subordinated notes.

The rating outlook for the Hercules, Calif.-based company is stable, Fitch said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.